Week down 4.5%, but Exosens share rebounds 2.5% during trading session
The Bordeaux-based optronic company is rising again in mid-morning trading, in a Paris market oriented towards purchases. This rebound occurs as its supply of neutron detectors to two American reactor designers has just been made public.
A rebound that has not yet recovered the moving averages
Exosens share gains 2.64% to €56.40, against €54.95 at the previous close, and the SBF 120 advances 0.94%. The security, however, still declines 4.57% over a week, and today's rebound leaves it 3.92% below its MA20 (€58.70). The MA50 and MA200, close to €60, also remain above the price.
The RSI at 39 draws a still weak configuration, away from the oversold zone. The support at €54.15, barely lost sight of after Thursday's session, bounds the recent pullback zone. This movement occurs in a market where the 10-year OAT yield stands at 4.90% according to the Banque de France survey of October 8, against the backdrop of tension in French debt.
Neutron detectors for the first two reactors in the DOE program
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In a press release dated October 8, 2026, Exosens states that it has supplied neutron detectors to Antares Nuclear and Valar Atomics. These two designers led the first two reactor models to achieve criticality as part of the Reactor Pilot Program of the U.S. Department of Energy. The announcement highlights the group's nuclear division, which manufactures neutron, gamma and ion detectors. On the agenda front, the publication of nine-month results is expected on October 27, following the upward revision of 2026 targets unveiled on September 17 (growth of approximately 20% in revenue and approximately 25% in adjusted EBITDA).
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
